Myelo Therapeutics
Latest round
- Series B
Last raised
- Jan 2016
Total raised
- Undisclosed
Investors
- 5
About Myelo Therapeutics
Myelo Therapeutics specializes in creating medical countermeasures for radiation exposure and supportive therapies for cancer treatment. The company has maintained a consistent strategy without significant pivots and is not known to have subsidiaries or parent companies. It was established in Berlin, Germany. The CEO is Dirk Pleimes, who has a background indicative of experience in biopharmaceutical ventures.Myelo Therapeutics GmbH specializes in the development of medical countermeasures and cancer-supportive care therapies designed to address the adverse effects of radiation exposure and chemotherapy. The company's core products aim to protect the public from lethal radiation attacks and offer therapeutic support for cancer patients experiencing unintended chemotherapy-related effects. Their innovative solutions are targeted toward healthcare facilities, hospitals, and governmental agencies that require advanced medical interventions in the event of radiation incidents.The revenue structure of Myelo Therapeutics GmbH encompasses several transactional models, primarily focusing on B2B partnerships with healthcare providers and governmental organizations. Transactions are facilitated through direct procurement agreements, enabling clients to acquire the company's flagship medical countermeasures and therapies suited for specific medical scenarios. Clients, including hospitals and cancer treatment centers, engage in contractual agreements outlining the purchase of products based on their therapeutic needs and available medical protocols.Myelo Therapeutics plans to expand its product line with new therapies focused on enhancing recovery from chemotherapy and radiation exposure. The company aims to enter additional markets in Asia and South America by 2023, informed by increasing demand for radiation safety products.
Who invested in Myelo Therapeutics
5 investors across 2 rounds
See all investors in Myelo Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Myelo Therapeutics
Who invested in Myelo Therapeutics?
Myelo Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Myelo Therapeutics raised?
Myelo Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Myelo Therapeutics last raise money?
Myelo Therapeutics's most recent round on record is a Series B, in Jan 2016.
What does Myelo Therapeutics do?
Myelo Therapeutics specializes in creating medical countermeasures for radiation exposure and supportive therapies for cancer treatment.
Where is Myelo Therapeutics headquartered?
Myelo Therapeutics is headquartered in Berlin, Germany.
Which VCs invest in companies like Myelo Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back healthcare specialists companies at Myelo Therapeutics's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series B
Raising like Myelo Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.